After Xtandi, Will Government Ever Seek March-In Rights Over Drug Pricing?

Xtandi march in
NIH rejects petition seeking march-in rights to prostate cancer drug patents • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock images

More from Pricing Debate

More from Market Access